Stock of the Day - December 16, 2021

Zentalis Pharmaceuticals (ZNTL)

$5.11

+$0.54 (+11.8%)

Market Cap: $325.32M

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Today's Trend

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) — Shares are trading higher after multiple sell‑side firms raised EPS forecasts and narrowed loss estimates for 2025–2027, signaling an improving earnings trajectory; that upside is partially offset by Morgan Stanley cutting its price target to $4 (while keeping an equal‑weight rating).

Analyst upgrades and tighter FY2025 estimates from HC Wainwright (Strong‑Buy) — the firm raised its FY2025 and FY2026 EPS forecasts and lifted Q4 2025 estimates, citing a smaller loss outlook that supports a brighter near‑term profile for the company. FY2025 Earnings Estimate for ZNTL Issued By HC Wainwright
Leerink Partnrs raised Q4 2025 and multi‑year EPS estimates (FY2025–FY2027), suggesting consensus losses are narrowing and analyst conviction is increasing across multiple desks. Leerink Partnrs Has Positive Outlook of ZNTL FY2025 Earnings
Wedbush boosted Q4 2025 and several future‑year forecasts (including FY2029 moving to a small positive EPS), and reiterated its Neutral stance with a $4 target — the upgrades reflect an expected path toward breakeven that investors may view as constructive. Wedbush Expects Higher Earnings for Zentalis Pharmaceuticals
Analysts issued updated near‑term (Q1 2026) estimates from both HC Wainwright and Wedbush — these set expectations for upcoming quarterly results but are incremental compared with the larger multi‑year forecast revisions. Analysts Set Expectations for ZNTL Q1 Earnings What is Wedbush's Forecast for ZNTL Q1 Earnings?
Morgan Stanley trimmed its price target from $8 to $4 (keeping an equal‑weight rating), which reduces the implied upside and may temper gains despite the EPS upgrades. Zentalis Pharmaceuticals Given New $4.00 Price Target at Morgan Stanley

Bottom line for investors: the primary driver of strength is a cluster of analyst forecast upgrades showing narrowing losses and a clearer multi‑year path to profitability; watch upcoming quarterly results and whether price‑target/ratings divergence (Morgan Stanley vs. HC Wainwright/Leerink) influences momentum.

← Previous Stock of the Day Next Stock of the Day →

Zentalis Pharmaceuticals (ZNTL)

About Zentalis Pharmaceuticals

Today's Trend

Recent News